The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Stryker met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share dropped significantly.
Gross margins expanded, operating margins shrank, net margins shrank.
Stryker chalked up revenue of $2.30 billion. The 27 analysts polled by S&P Capital IQ wanted to see a top line of $2.28 billion on the same basis. GAAP reported sales were 5.5% higher than the prior-year quarter's $2.22 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.14. The 28 earnings estimates compiled by S&P Capital IQ predicted $1.13 per share. GAAP EPS of $0.71 for Q4 were 32% lower than the prior-year quarter's $1.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.2%, 90 basis points better than the prior-year quarter. Operating margin was 17.1%, 700 basis points worse than the prior-year quarter. Net margin was 11.6%, 650 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $2.21 billion. On the bottom line, the average EPS estimate is $1.02.
Next year's average estimate for revenue is $8.96 billion. The average EPS estimate is $4.31.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,445 members out of 1,477 rating the stock outperform, and 32 members rating it underperform. Among 471 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 462 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $59.68.
Is Stryker the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Stryker to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.